EnClear Therapies software

ELC1: LEPTOMENINGEAL CARCINOMATOSIS (LC). A devastating form of Cancer effecting 110,000 Patients/Yr. US, with a current life expectancy 2-7 months. Involvement by cancer of pia & arachnoid mater of the brain with the subarachnoid space in between. High incidence from breast, lung & melanoma.

Localized CNS delivery of therapeutics & monitoring of CSF to ensure effective & personalized therapy. Closed loop CSF control & integrated ML/AI, the EnClear Therapies CSF health platform provides Precision Dosing of CNS based therapeutics to obtain efficacious levels, while reducing risk of severe side effects and peripheral toxicity.